Vietnam Oral Anti Diabetic Drug Market Report by Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides), and Region 2024-2032
收藏www.imarcgroup.com2025-01-22 收录
下载链接：
https://www.imarcgroup.com/vietnam-oral-anti-diabetic-drug-market
下载链接
链接失效反馈官方服务：
资源简介：
<h4><strong>Market Overview:</strong></h4>
<blockquote>
<p><em>Vietnam oral anti diabetic drug market size is projected to exhibit a growth rate (CAGR) of </em>3.56%<em> during </em>2024-2032<em>. The rising prevalence of diabetes, the introduction of a diverse range of oral anti-diabetic drugs, the rapid expansion of healthcare facilities and the easy availability of skilled healthcare professionals represent some of the key factors driving the market.</em></p>
</blockquote>
<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="width:70%">
<div style="text-align:left"><strong>Report Attribute</strong></div>
</th>
<th scope="col">
<div>Key Statistics</div>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<div><strong>Base Year</strong></div>
</td>
<td>2023</td>
</tr>
<tr>
<td>
<div><strong>Forecast Years</strong></div>
</td>
<td>2024-2032</td>
</tr>
<tr>
<td>
<div><strong>Historical Years</strong></div>
</td>
<td>
<div>2018-2023</div>
</td>
</tr>
<tr>
<td><strong>Market Growth Rate (2024-2032)</strong></td>
<td>3.56%</td>
</tr>
</tbody>
</table>
<p><br />
Oral anti-diabetic drugs are pharmaceutical medications designed to manage and control high blood sugar levels in individuals with diabetes mellitus. These drugs are taken orally, typically in the form of tablets or capsules, and work by various mechanisms to help regulate blood glucose levels. They are an essential component of diabetes management, often used alongside lifestyle modifications and insulin therapy. The primary goal of oral anti-diabetic drugs is to lower blood sugar levels within a healthy range, thus reducing the risk of complications associated with diabetes, such as cardiovascular disease, kidney problems, and nerve damage. These medications work in different ways, including stimulating insulin production, increasing insulin sensitivity in cells, or slowing down the absorption of glucose from the digestive tract. It is crucial for individuals with diabetes to work closely with healthcare professionals to determine the most suitable oral anti-diabetic drug(s) based on their specific needs and medical history. Regular monitoring of blood glucose levels and adherence to prescribed medication regimens are essential to achieve effective diabetes management and maintain overall health.</p>
<h4><strong>Vietnam Oral Anti Diabetic Drug Market Trends:</strong></h4>
<p>The rising prevalence of diabetes among the masses due to changes in lifestyle, dietary habits, and an aging population is driving the global market. This has created a substantial patient pool in need of oral anti-diabetic medications, thereby impelling the market. Moreover, government initiatives have also played a crucial role in catalyzing this market. The Vietnamese government has taken steps to improve healthcare access and affordability, including providing support for diabetes management programs. This has made oral anti-diabetic drugs more accessible to a broader segment of the population. Furthermore, pharmaceutical companies operating in Vietnam have been actively introducing and promoting innovative oral anti-diabetic drugs. These companies are investing heavily in research and development (R&D) activities to bring new, more effective medications to the market, which is acting as a significant growth-inducing factor. Apart from this, the easy availability of a diverse range of oral anti-diabetic drugs with varying mechanisms of action has provided healthcare professionals with more treatment options, which in turn is increasing the overall market demand. Besides this, the heightened awareness about diabetes and its management has played a pivotal role. Health campaigns and educational efforts have helped inform the public about the importance of early diagnosis and treatment of diabetes, thereby leading to a higher demand for oral anti-diabetic drugs as part of diabetes management. Additionally, healthcare infrastructure improvements have made it easier for patients to access healthcare services, including diabetes diagnosis and treatment, which is fueling the market. The expansion of healthcare facilities and the rising number of skilled healthcare professionals are also contributing to the growth of the oral anti-diabetic drug market. </p>
<h4 style="text-align:justify"><strong>Vietnam Oral Anti Diabetic Drug Market Segmentation:</strong></h4>
<p style="text-align:justify">IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on oral anti-diabetic drugs.</p>
<p style="text-align:justify"><strong>Oral Anti-Diabetic Drugs Insights:</strong></p>
<p style="text-align:center"><strong><img alt="Vietnam Oral Anti Diabetic Drug Market Report" src="https://www.imarcgroup.com/CKEditor/536a9dba-1260-4cc0-b5d1-5d068f061661vietnam-oral-anti-diabetic-drug-market-sagment.webp" style="height:450px; width:800px" /></strong></p>
<ul>
<li>Biguanides</li>
<li>Alpha-Glucosidase Inhibitors</li>
<li>Dopamine D2 Receptor Agonist</li>
<li>SGLT-2 Inhibitors
<ul style="list-style-type:circle">
<li>Invokana (Canagliflozin)</li>
<li>Jardiance (Empagliflozin)</li>
<li>Farxiga/Forxiga (Dapagliflozin)</li>
<li>Suglat (Ipragliflozin)</li>
</ul>
</li>
<li>DPP-4 Inhibitors
<ul style="list-style-type:circle">
<li>Onglyza (Saxagliptin)</li>
<li>Tradjenta (Linagliptin)</li>
<li>Vipidia/Nesina (Alogliptin)</li>
<li>Galvus (Vildagliptin)</li>
</ul>
</li>
<li>Sulfonylureas</li>
<li>Meglitinides<br />
</li>
</ul>
<p style="text-align:justify">The report has provided a detailed breakup and analysis of the market based on the oral anti-diabetic drugs. This includes biguanides, alpha-glucosidase inhibitors, dopamine d2 receptor agonist, sglt-2 inhibitors {(invokana (canagliflozin), jardiance (empagliflozin), farxiga/forxiga (dapagliflozin), suglat (ipragliflozin)}, dpp-4 inhibitors {(onglyza (saxagliptin), tradjenta (linagliptin), vipidia/nesina (alogliptin), galvus (vildagliptin)}, sulfonylureas, and meglitinides.</p>
<p style="text-align:justify"><strong>Regional Insights:</strong></p>
<p style="text-align:center"><strong><img alt="Vietnam Oral Anti Diabetic Drug Market Report" src="https://www.imarcgroup.com/CKEditor/06ba01cd-2c1f-4d95-8c72-f4b964e52d66vietnam-oral-anti-diabetic-drug-market-regional.webp" style="height:450px; width:800px" /></strong></p>
<ul>
<li style="text-align:justify">Northern Vietnam</li>
<li style="text-align:justify">Central Vietnam</li>
<li style="text-align:justify">Southern Vietnam<br />
</li>
</ul>
<p style="text-align:justify">The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Vietnam, Central Vietnam, and Southern Vietnam.</p>
<h4 style="text-align:justify"><strong>Competitive Landscape:</strong></h4>
<p style="text-align:justify">The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.</p>
<h4 style="text-align:justify"><strong>Vietnam Oral Anti Diabetic Drug Market Report Coverage:</strong></h4>
<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr">
<thead>
<tr>
<th scope="col" style="width:40%">Report Features</th>
<th scope="col">Details</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center">Base Year of the Analysis</td>
<td style="text-align:center">2023</td>
</tr>
<tr>
<td style="text-align:center"> Historical Period</td>
<td style="text-align:center">2018-2023</td>
</tr>
<tr>
<td style="text-align:center">Forecast Period</td>
<td style="text-align:center">2024-2032</td>
</tr>
<tr>
<td style="text-align:center">Units</td>
<td style="text-align:center">US$ Million</td>
</tr>
<tr>
<td style="text-align:center">Scope of the Report</td>
<td style="text-align:center">Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
<ul>
<li style="text-align:justify">Oral Anti-Diabetic Drugs</li>
<li style="text-align:left">Region</li>
</ul>
</td>
</tr>
<tr>
<td style="text-align:center">Oral Anti-Diabetic Drugs Covered</td>
<td style="text-align:center">
<ul>
<li style="text-align:left"><strong>Biguanides</strong></li>
<li style="text-align:left"><strong>Alpha-Glucosidase Inhibitors</strong></li>
<li style="text-align:left"><strong>Dopamine D2 Receptor Agonist</strong></li>
<li style="text-align:left"><strong>SGLT-2 Inhibitors: </strong>Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin)</li>
<li style="text-align:left"><strong>DPP-4 Inhibitors: </strong>Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), Galvus (Vildagliptin)</li>
<li style="text-align:left"><strong>Sulfonylureas</strong></li>
<li style="text-align:left"><strong>Meglitinides</strong></li>
</ul>
</td>
</tr>
<tr>
<td style="text-align:center">Regions Covered</td>
<td style="text-align:center">Northern Vietnam, Central Vietnam, Southern Vietnam</td>
</tr>
<tr>
<td style="text-align:center">Customization Scope</td>
<td style="text-align:center">10% Free Customization</td>
</tr>
<tr>
<td style="text-align:center">Report Price and Purchase Option</td>
<td style="text-align:center">Single User License: US$ 3699<br />
Five User License: US$ 4699<br />
Corporate License: US$ 5699</td>
</tr>
<tr>
<td style="text-align:center">Post-Sale Analyst Support</td>
<td style="text-align:center">10-12 Weeks</td>
</tr>
<tr>
<td style="text-align:center">Delivery Format</td>
<td style="text-align:center">PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)</td>
</tr>
</tbody>
</table>
<h4 style="text-align:justify"><strong>Key Questions Answered in This Report:</strong></h4>
<ul>
<li style="text-align:justify">How has the Vietnam oral anti diabetic drug market performed so far and how will it perform in the coming years?</li>
<li style="text-align:justify">What has been the impact of COVID-19 on the Vietnam oral anti diabetic drug market?</li>
<li style="text-align:justify">What is the breakup of the Vietnam oral anti diabetic drug market on the basis of oral anti-diabetic drugs?</li>
<li style="text-align:justify">What are the various stages in the value chain of the Vietnam oral anti diabetic drug market? </li>
<li style="text-align:justify">What are the key driving factors and challenges in the Vietnam oral anti diabetic drug?</li>
<li style="text-align:justify">What is the structure of the Vietnam oral anti diabetic drug market and who are the key players?</li>
<li style="text-align:justify">What is the degree of competition in the Vietnam oral anti diabetic drug market? </li>
</ul>
<h4 style="text-align:justify"><strong>Key Benefits for Stakeholders:</strong></h4>
<ul>
<li style="text-align:justify">IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Vietnam oral anti diabetic drug market from 2018-2032.</li>
<li style="text-align:justify">The research report provides the latest information on the market drivers, challenges, and opportunities in the Vietnam oral anti diabetic drug market.</li>
<li style="text-align:justify">Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Vietnam oral anti diabetic drug industry and its attractiveness.</li>
<li style="text-align:justify">Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.</li>
</ul>
<h4><strong>市场概览：</strong></h4>
<blockquote>
<p><em>越南口服抗糖尿病药物市场规模预计将在2024-2032年间以3.56%的复合年增长率（CAGR）增长。糖尿病患病率的上升、多种口服抗糖尿病药物的引入、医疗保健设施的快速扩张以及熟练医疗保健专业人员的易于获得是推动市场增长的关键因素。</em></p>
</blockquote>
<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="width:70%">
<div style="text-align:left"><strong>报告属性</strong></div>
</th>
<th scope="col">
<div>关键统计数据</div>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<div><strong>基准年</strong></div>
</td>
<td>2023</td>
</tr>
<tr>
<td>
<div><strong>预测年</strong></div>
</td>
<td>2024-2032</td>
</tr>
<tr>
<td>
<div><strong>历史年</strong></div>
</td>
<td>
<div>2018-2023</div>
</td>
</tr>
<tr>
<td><strong>市场增长率（2024-2032年）</strong></td>
<td>3.56%</td>
</tr>
</tbody>
</table>
<p><br />
口服抗糖尿病药物是一种旨在管理和控制糖尿病个体高血糖水平的药物。这些药物通常以片剂或胶囊的形式口服，通过多种机制帮助调节血糖水平。它们是糖尿病管理的重要组成部分，常与生活方式的改变和胰岛素疗法同时使用。口服抗糖尿病药物的主要目标是降低血糖水平至健康范围，从而降低与糖尿病相关的并发症风险，如心血管疾病、肾脏问题和神经损伤。这些药物通过不同的方式发挥作用，包括刺激胰岛素产生、增加细胞对胰岛素的敏感性或减缓葡萄糖从消化道的吸收。对于糖尿病患者而言，与医疗保健专业人员紧密合作，根据其特定需求和病史确定最合适的口服抗糖尿病药物至关重要。定期监测血糖水平和遵守处方药物方案对于实现有效的糖尿病管理和维持整体健康至关重要。</p>
<h4><strong>越南口服抗糖尿病药物市场趋势：</strong></h4>
<p>由于生活方式、饮食习惯的改变以及人口老龄化，糖尿病在大众中的患病率上升，推动了全球市场。这创造了一个庞大的患者群体，需要口服抗糖尿病药物，从而推动了市场。此外，政府倡议也在此市场中发挥了关键作用。越南政府已采取措施改善医疗保健的可获得性和可负担性，包括为糖尿病管理计划提供支持。这使得口服抗糖尿病药物对更广泛的群体更具可及性。此外，在越南运营的制药公司积极推出和推广创新的口服抗糖尿病药物。这些公司正在投入大量资金进行研发（R&D）活动，以将新的、更有效的药物推向市场，这成为推动市场增长的重要因素。除此之外，易于获得的具有不同作用机制的多种口服抗糖尿病药物为医疗保健专业人员提供了更多的治疗方案，从而增加了整体市场需求。此外，对糖尿病及其管理的认识提高也发挥了关键作用。健康运动和教育努力帮助公众了解早期诊断和治疗糖尿病的重要性，从而推动了作为糖尿病管理一部分的口服抗糖尿病药物的需求。此外，医疗保健基础设施的改善使患者更容易获得医疗保健服务，包括糖尿病诊断和治疗，这推动了市场。医疗保健设施的发展和熟练医疗保健专业人员的增加也对口服抗糖尿病药物市场的发展做出了贡献。</p>
<h4 style="text-align:justify"><strong>越南口服抗糖尿病药物市场细分：</strong></h4>
<p style="text-align:justify">IMARC Group对市场每个细分市场的主要趋势进行了分析，并为2024-2032年在国家层面进行了预测。我们的报告根据口服抗糖尿病药物对市场进行了分类。</p>
<p style="text-align:justify"><strong>口服抗糖尿病药物洞察：</strong></p>
<p style="text-align:center"><strong><img alt="Vietnam Oral Anti Diabetic Drug Market Report" src="https://www.imarcgroup.com/CKEditor/536a9dba-1260-4cc0-b5d1-5d068f061661vietnam-oral-anti-diabetic-drug-market-sagment.webp" style="height:450px; width:800px" /></strong></p>
<ul>
<li>双胍类</li>
<li>α-葡萄糖苷酶抑制剂</li>
<li>多巴胺D2受体激动剂</li>
<li>SGLT-2抑制剂
<ul style="list-style-type:circle">
<li>Invokana (Canagliflozin)</li>
<li>Jardiance (Empagliflozin)</li>
<li>Farxiga/Forxiga (Dapagliflozin)</li>
<li>Suglat (Ipragliflozin)</li>
</ul>
</li>
<li>DPP-4抑制剂
<ul style="list-style-type:circle">
<li>Onglyza (Saxagliptin)</li>
<li>Tradjenta (Linagliptin)</li>
<li>Vipidia/Nesina (Alogliptin)</li>
<li>Galvus (Vildagliptin)</li>
</ul>
</li>
<li>磺酰脲类</li>
<li>麦格利汀类<br />
</li>
</ul>
<p style="text-align:justify">报告已根据口服抗糖尿病药物对市场进行了详细的分解和分析。这包括双胍类、α-葡萄糖苷酶抑制剂、多巴胺D2受体激动剂、SGLT-2抑制剂（Invokana（Canagliflozin）、Jardiance（Empagliflozin）、Farxiga/Forxiga（Dapagliflozin）、Suglat（Ipragliflozin））、DPP-4抑制剂（Onglyza（Saxagliptin）、Tradjenta（Linagliptin）、Vipidia/Nesina（Alogliptin）、Galvus（Vildagliptin））、磺酰脲类和麦格利汀类。</p>
<p style="text-align:justify"><strong>区域洞察：</strong></p>
<p style="text-align:center"><strong><img alt="Vietnam Oral Anti Diabetic Drug Market Report" src="https://www.imarcgroup.com/CKEditor/06ba01cd-2c1f-4d95-8c72-f4b964e52d66vietnam-oral-anti-diabetic-drug-market-regional.webp" style="height:450px; width:800px" /></strong></p>
<ul>
<li style="text-align:justify">越南北部</li>
<li style="text-align:justify">越南中部</li>
<li style="text-align:justify">越南南部<br />
</li>
</ul>
<p style="text-align:justify">报告还全面分析了所有主要区域市场，包括越南北部、越南中部和越南南部。</p>
<h4 style="text-align:justify"><strong>竞争格局：</strong></h4>
<p style="text-align:justify">市场研究报告还全面分析了市场的竞争格局。包括市场结构、关键玩家定位、主要获胜策略、竞争仪表板和公司评估象限等竞争分析已包含在报告中。同时，还提供了所有主要公司的详细资料。</p>
<h4 style="text-align:justify"><strong>越南口服抗糖尿病药物市场报告覆盖范围：</strong></h4>
<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr">
<thead>
<tr>
<th scope="col" style="width:40%">报告特点</th>
<th scope="col">详细信息</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center">分析基准年</td>
<td style="text-align:center">2023</td>
</tr>
<tr>
<td style="text-align:center"> 历史时期</td>
<td style="text-align:center">2018-2023</td>
</tr>
<tr>
<td style="text-align:center">预测时期</td>
<td style="text-align:center">2024-2032</td>
</tr>
<tr>
<td style="text-align:center">单位</td>
<td style="text-align:center">US$ 百万</td>
</tr>
<tr>
<td style="text-align:center">报告范围</td>
<td style="text-align:center">历史趋势和市场展望的探索、行业催化剂和挑战、按细分市场的历史和未来市场评估：
<ul>
<li style="text-align:justify">口服抗糖尿病药物</li>
<li style="text-align:left">地区</li>
</ul>
</td>
</tr>
<tr>
<td style="text-align:center">覆盖的口服抗糖尿病药物</td>
<td style="text-align:center">
<ul>
<li style="text-align:left"><strong>双胍类</strong></li>
<li style="text-align:left"><strong>α-葡萄糖苷酶抑制剂</strong></li>
<li style="text-align:left"><strong>多巴胺D2受体激动剂</strong></li>
<li style="text-align:left"><strong>SGLT-2抑制剂：</strong>Invokana（Canagliflozin）、Jardiance（Empagliflozin）、Farxiga/Forxiga（Dapagliflozin）、Suglat（Ipragliflozin）</li>
<li style="text-align:left"><strong>DPP-4抑制剂：</strong>Onglyza（Saxagliptin）、Tradjenta（Linagliptin）、Vipidia/Nesina（Alogliptin）、Galvus（Vildagliptin）</li>
<li style="text-align:left"><strong>磺酰脲类</strong></li>
<li style="text-align:left"><strong>麦格利汀类</strong></li>
</ul>
</td>
</tr>
<tr>
<td style="text-align:center">覆盖的地区</td>
<td style="text-align:center">越南北部、越南中部、越南南部</td>
</tr>
<tr>
<td style="text-align:center">定制范围</td>
<td style="text-align:center">10% 免费定制</td>
</tr>
<tr>
<td style="text-align:center">报告价格和购买选项</td>
<td style="text-align:center">单用户许可：US$ 3699<br />
五用户许可：US$ 4699<br />
企业许可：US$ 5699</td>
</tr>
<tr>
<td style="text-align:center">售后分析师支持</td>
<td style="text-align:center">10-12 周</td>
</tr>
<tr>
<td style="text-align:center">交付格式</td>
<td style="text-align:center">PDF和Excel通过电子邮件（根据特殊要求，我们还可以提供PPT/Word格式的可编辑报告版本）</td>
</tr>
</tbody>
</table>
<h4 style="text-align:justify"><strong>本报告回答的关键问题：</strong></h4>
<ul>
<li style="text-align:justify">越南口服抗糖尿病药物市场迄今为止的表现如何？未来几年将如何表现？</li>
<li style="text-align:justify">COVID-19对越南口服抗糖尿病药物市场有何影响？</li>
<li style="text-align:justify">根据口服抗糖尿病药物，越南口服抗糖尿病药物市场是如何划分的？</li>
<li style="text-align:justify">越南口服抗糖尿病药物市场的价值链有哪些不同阶段？</li>
<li style="text-align:justify">越南口服抗糖尿病药物市场的主要驱动因素和挑战是什么？</li>
<li style="text-align:justify">越南口服抗糖尿病药物市场的结构如何？主要玩家是谁？</li>
<li style="text-align:justify">越南口服抗糖尿病药物市场的竞争程度如何？</li>
</ul>
<h4 style="text-align:justify"><strong>为利益相关者提供的关键优势：</strong></h4>
<ul>
<li style="text-align:justify">IMARC的行业报告提供了对各个市场细分、历史和当前市场趋势、市场预测和市场动态的全面定量分析，涵盖2018-2032年的越南口服抗糖尿病药物市场。</li>
<li style="text-align:justify">研究报告提供了越南口服抗糖尿病药物市场中的市场驱动因素、挑战和机遇的最新信息。</li>
<li style="text-align:justify">波特五力分析帮助利益相关者评估新进入者、竞争激烈程度、供应商力量、购买者和替代威胁的影响。它帮助利益相关者分析越南口服抗糖尿病药物行业的竞争程度及其吸引力。</li>
<li style="text-align:justify">竞争格局使利益相关者能够了解其竞争环境，并为关键玩家在市场中的当前位置提供洞察。</li>
</ul>
提供机构：
IMARC Group
